ArticleClinical case reports2026
A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 19-year-old female with schizophrenia developed severe mixed tardive syndrome (choreoathetoid dyskinesia with prominent tardive dystonia) after antipsychotic treatment, which remained debilitating despite deutetrabenazine, benzodiazepines, baclofen, and amantadine. Over a 39-day inpatient stay, switching the antipsychotic to clozapine and adding botulinum toxin injections plus the central muscle relaxant eperisone led to dramatic improvement, with the Abnormal Involuntary Movement Scale (AIMS) score falling from 32 to 8. Her psychosis also stabilized (PANSS 70 → 44). At 2-month follow-up, the regimen was simplified with sustained benefit. This case illustrates that a multimodal strategy-combining a low-D2-affinity antipsychotic, a VMAT2 inhibitor, and targeted muscle relaxation-was associated with marked improvement in this patient with refractory mixed tardive syndrome. However, given the near-simultaneous implementation of multiple interventions, the relative contribution of each component cannot be definitively determined, and controlled studies are needed to establish the efficacy of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.